Results 121 to 130 of about 76,206 (274)

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

N-imidazolebenzyl-histidine substitution in somatostatin and in its octapeptide analogue modulates receptor selectivity and function

, 2011
Despite 3 decades of focused chemical, biological, structural, and clinical developments, unusual properties of somatostatin (SRIF, 1) analogues are still being uncovered. Here we report the unexpected functional properties of 1 and the octapeptide cyclo(
Rivier, Jean E, Erchegyi, Judit, Judit Erchegyi, Cescato, Renzo, Beatrice Waser, Renzo Cescato, Jean E. Rivier, Waser, Beatrice, Jean Claude Reubi, Reubi, Jean-Claude   +9 more
core   +1 more source

Prevention of microglial activation and postoperative cognitive deficits by positive allosteric modulation of α5‐GABAA receptors

British Journal of Pharmacology, EarlyView.
Background and Purpose Long‐lasting cognitive deficits after surgery in aged individuals, referred to as perioperative neurocognitive disorder (NCD), are a significant public health concern. Such postoperative cognitive deficits are dependent on the presence of microglia in the brain, which, when activated, trigger neuroinflammation.
Jinrui Lyu, Rajasekar Nagarajan, Dishary Sharmin, Prithu Mondal, Maltesh Kambali, Muxiao Wang, Jinyan Zhou, Makoto Inoue, James M. Cook, Uwe Rudolph   +9 more
wiley   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Antiangiogenic effects of somatostatin analogues.

, 2002
Inhibition of angiogenesis has become a target for antineoplastic therapy and for treatment of retinal neovascularization. The presence of somatostatin receptors on tumour cells and on the proliferating vascular endothelium has led to several in vitro ...
J. A. H. Wass, García de la Torre, N, N. García De La Torre, Wass, JA, Turner, HE, H. E. Turner   +5 more
core   +1 more source

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes, Florian Buehning, Tobias Lerchner, Julia Vogel, Raluca I. Mincu, Matthias Totzeck, Tienush Rassaf, Lars Michel   +7 more
wiley   +1 more source

Impact of Osilodrostat on Health‐Related Quality of Life in Cushing's Disease: Analysis of Patient‐Reported Outcomes From the Phase III LINC 3 and LINC 4 Clinical Trials

Clinical Endocrinology, EarlyView.
ABSTRACT Objective Evaluate the effects of osilodrostat short‐ and long‐term treatment on health‐related quality of life (HRQoL) in Cushing's disease. Design LINC 3 and LINC 4 studies (pooled analysis). Patients 185 patients (mean baseline total scores: Cushing's Quality of Life [CushingQoL], 44.0; Beck Depression Inventory II [BDI‐II], 15.6; EuroQol ...
John Newell‐Price, Beverly M. K. Biller, Maria Fleseriu, Beatrice Gueron, Grzegorz Binowski, Anna Paćkowska, Mônica R. Gadelha   +6 more
wiley   +1 more source

Antitumor effects of somatostatin.

, 2008
International audienceSince its discovery three decades ago as an inhibitor of GH release from the pituitary gland, somatostatin has attracted much attention because of its functional role in the regulation of a wide variety of physiological functions in
Najib, Souad, Laklai, Hanane, Bousquet, Corinne, Azar, Rania, Susini, Christiane, Pyronnet, Stéphane   +5 more
core   +1 more source

Inflammatory Cytokines Impair Glucagon Expression and Secretion in Pancreatic α‐Cells

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Insulin resistance and obesity‐associated inflammation are key drivers in the pathogenesis of Type 2 diabetes mellitus (T2DM). Whilst inflammatory cytokines are well known to impair β‐cell function, their impact on pancreatic α‐cells and glucagon (GCG) regulation remains poorly understood. In this study, we investigated the effects of the
Caroline Bickelmann, Cedric Wilden, Leticia Prates‐Roma, Matthias W. Laschke, Emmanuel Ampofo, Selina Wrublewsky   +5 more
wiley   +1 more source

One Week Exposure to a Somatostatin Receptor 2 Antagonist (SSTR2a) Enhances Glucagon Counterregulation to Insulin‐Induced Hypoglycaemia and Does Not Worsen Glycemia in a Male Rat Model of Insulin‐Requiring Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Introduction Administration of a somatostatin receptor 2 antagonist (SSTR2a) increases glucagon responsiveness to hypoglycaemia in insulin‐treated type 2 diabetes (T2D), but the durability of this effect and the impact of repeated SSTR2a dosing on overall glycaemia in T2D are unclear.
Ninoschka C. D'Souza, Emily G. Hoffman, Sara C. Atherley, Sabrina Champsi, Nadia Aleali, Richard T. Liggins, Owen Chan, Michael C. Riddell   +7 more
wiley   +1 more source